Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation

Global utilization of strategies to open occluded coronary arteries trial IV in acute coronary syndromes (GUSTO IV ACS) Italian hematologic substudy

Piera Angelica Merlini, Alessandra Repetto, Alessandro Lombardi, Alfredo Vetrano, Raffaela Fetiveau, Claudio Cavallini, Diego Sappè, Alessandro Salvioni, Roberto Canziani, Stefano Savonitto, Pier Mannuccio Mannucci, Diego Ardissino

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background - Abciximab is very effective in reducing major cardiac events in patients undergoing interventional procedures. Its antithrombotic effect is primarily attributable to the blocking of platelet glycoprotein IIb/IIIa receptors, but recent evidence suggests that it may have a direct antithrombin effect. No data are available concerning the effect of abciximab on the in vivo markers of prothrombin activation and thrombin generation in patients with acute coronary syndromes without ST elevation. Methods and Results - We measured the plasma levels of prothrombin fragment 1 + 2 (a marker of prothrombin activation) and the thrombin/antithrombin complex (a marker of thrombin generation) in 167 patients with acute coronary syndromes without ST elevation enrolled in the GUSTO IV ACS trial who were randomized to receive abciximab for 24 hours (52 patients), abciximab for 48 hours (59 patients), or placebo (56 patients) in addition to heparin. Blood samples were obtained at baseline (before any treatment), after 24 and 48 hours (before study drug discontinuation), and 1 month later. There was a significant increase in the plasma levels of prothrombin fragment 1 + 2 after 48 hours and after 1 month in all 3 groups, placebo (P=0.0001), 24-hour abciximab (P=0.0002), and 48-hour abciximab (P=0.0001). The plasma thrombin/antithrombin complex levels were similar in the 3 groups at all time points and did not change during the study drug infusions. Conclusions - Abciximab does not decrease prothrombin activation and thrombin generation in patients with acute coronary syndromes without ST elevation not undergoing interventional procedures.

Original languageEnglish
Pages (from-to)928-932
Number of pages5
JournalCirculation
Volume105
Issue number8
DOIs
Publication statusPublished - Feb 26 2002

Fingerprint

Prothrombin
Acute Coronary Syndrome
Thrombin
Coronary Vessels
Placebos
Integrin beta3
Platelet Glycoprotein GPIIb-IIIa Complex
Antithrombins
abciximab
Pharmaceutical Preparations
Heparin

Keywords

  • Coronary disease
  • Glycoproteins
  • Inhibitors
  • Thrombin

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation : Global utilization of strategies to open occluded coronary arteries trial IV in acute coronary syndromes (GUSTO IV ACS) Italian hematologic substudy. / Merlini, Piera Angelica; Repetto, Alessandra; Lombardi, Alessandro; Vetrano, Alfredo; Fetiveau, Raffaela; Cavallini, Claudio; Sappè, Diego; Salvioni, Alessandro; Canziani, Roberto; Savonitto, Stefano; Mannucci, Pier Mannuccio; Ardissino, Diego.

In: Circulation, Vol. 105, No. 8, 26.02.2002, p. 928-932.

Research output: Contribution to journalArticle

@article{0d7356f8c422491aaffd155854a2ce2c,
title = "Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: Global utilization of strategies to open occluded coronary arteries trial IV in acute coronary syndromes (GUSTO IV ACS) Italian hematologic substudy",
abstract = "Background - Abciximab is very effective in reducing major cardiac events in patients undergoing interventional procedures. Its antithrombotic effect is primarily attributable to the blocking of platelet glycoprotein IIb/IIIa receptors, but recent evidence suggests that it may have a direct antithrombin effect. No data are available concerning the effect of abciximab on the in vivo markers of prothrombin activation and thrombin generation in patients with acute coronary syndromes without ST elevation. Methods and Results - We measured the plasma levels of prothrombin fragment 1 + 2 (a marker of prothrombin activation) and the thrombin/antithrombin complex (a marker of thrombin generation) in 167 patients with acute coronary syndromes without ST elevation enrolled in the GUSTO IV ACS trial who were randomized to receive abciximab for 24 hours (52 patients), abciximab for 48 hours (59 patients), or placebo (56 patients) in addition to heparin. Blood samples were obtained at baseline (before any treatment), after 24 and 48 hours (before study drug discontinuation), and 1 month later. There was a significant increase in the plasma levels of prothrombin fragment 1 + 2 after 48 hours and after 1 month in all 3 groups, placebo (P=0.0001), 24-hour abciximab (P=0.0002), and 48-hour abciximab (P=0.0001). The plasma thrombin/antithrombin complex levels were similar in the 3 groups at all time points and did not change during the study drug infusions. Conclusions - Abciximab does not decrease prothrombin activation and thrombin generation in patients with acute coronary syndromes without ST elevation not undergoing interventional procedures.",
keywords = "Coronary disease, Glycoproteins, Inhibitors, Thrombin",
author = "Merlini, {Piera Angelica} and Alessandra Repetto and Alessandro Lombardi and Alfredo Vetrano and Raffaela Fetiveau and Claudio Cavallini and Diego Sapp{\`e} and Alessandro Salvioni and Roberto Canziani and Stefano Savonitto and Mannucci, {Pier Mannuccio} and Diego Ardissino",
year = "2002",
month = "2",
day = "26",
doi = "10.1161/hc0802.104456",
language = "English",
volume = "105",
pages = "928--932",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation

T2 - Global utilization of strategies to open occluded coronary arteries trial IV in acute coronary syndromes (GUSTO IV ACS) Italian hematologic substudy

AU - Merlini, Piera Angelica

AU - Repetto, Alessandra

AU - Lombardi, Alessandro

AU - Vetrano, Alfredo

AU - Fetiveau, Raffaela

AU - Cavallini, Claudio

AU - Sappè, Diego

AU - Salvioni, Alessandro

AU - Canziani, Roberto

AU - Savonitto, Stefano

AU - Mannucci, Pier Mannuccio

AU - Ardissino, Diego

PY - 2002/2/26

Y1 - 2002/2/26

N2 - Background - Abciximab is very effective in reducing major cardiac events in patients undergoing interventional procedures. Its antithrombotic effect is primarily attributable to the blocking of platelet glycoprotein IIb/IIIa receptors, but recent evidence suggests that it may have a direct antithrombin effect. No data are available concerning the effect of abciximab on the in vivo markers of prothrombin activation and thrombin generation in patients with acute coronary syndromes without ST elevation. Methods and Results - We measured the plasma levels of prothrombin fragment 1 + 2 (a marker of prothrombin activation) and the thrombin/antithrombin complex (a marker of thrombin generation) in 167 patients with acute coronary syndromes without ST elevation enrolled in the GUSTO IV ACS trial who were randomized to receive abciximab for 24 hours (52 patients), abciximab for 48 hours (59 patients), or placebo (56 patients) in addition to heparin. Blood samples were obtained at baseline (before any treatment), after 24 and 48 hours (before study drug discontinuation), and 1 month later. There was a significant increase in the plasma levels of prothrombin fragment 1 + 2 after 48 hours and after 1 month in all 3 groups, placebo (P=0.0001), 24-hour abciximab (P=0.0002), and 48-hour abciximab (P=0.0001). The plasma thrombin/antithrombin complex levels were similar in the 3 groups at all time points and did not change during the study drug infusions. Conclusions - Abciximab does not decrease prothrombin activation and thrombin generation in patients with acute coronary syndromes without ST elevation not undergoing interventional procedures.

AB - Background - Abciximab is very effective in reducing major cardiac events in patients undergoing interventional procedures. Its antithrombotic effect is primarily attributable to the blocking of platelet glycoprotein IIb/IIIa receptors, but recent evidence suggests that it may have a direct antithrombin effect. No data are available concerning the effect of abciximab on the in vivo markers of prothrombin activation and thrombin generation in patients with acute coronary syndromes without ST elevation. Methods and Results - We measured the plasma levels of prothrombin fragment 1 + 2 (a marker of prothrombin activation) and the thrombin/antithrombin complex (a marker of thrombin generation) in 167 patients with acute coronary syndromes without ST elevation enrolled in the GUSTO IV ACS trial who were randomized to receive abciximab for 24 hours (52 patients), abciximab for 48 hours (59 patients), or placebo (56 patients) in addition to heparin. Blood samples were obtained at baseline (before any treatment), after 24 and 48 hours (before study drug discontinuation), and 1 month later. There was a significant increase in the plasma levels of prothrombin fragment 1 + 2 after 48 hours and after 1 month in all 3 groups, placebo (P=0.0001), 24-hour abciximab (P=0.0002), and 48-hour abciximab (P=0.0001). The plasma thrombin/antithrombin complex levels were similar in the 3 groups at all time points and did not change during the study drug infusions. Conclusions - Abciximab does not decrease prothrombin activation and thrombin generation in patients with acute coronary syndromes without ST elevation not undergoing interventional procedures.

KW - Coronary disease

KW - Glycoproteins

KW - Inhibitors

KW - Thrombin

UR - http://www.scopus.com/inward/record.url?scp=0037176934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037176934&partnerID=8YFLogxK

U2 - 10.1161/hc0802.104456

DO - 10.1161/hc0802.104456

M3 - Article

VL - 105

SP - 928

EP - 932

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 8

ER -